Sar­to­rius, Repli­gen to in­tro­duce Next-Gen per­fu­sion-en­abled biore­ac­tors

BioSpectrum (Asia) - - Supplier News -

Sar­to­rius Ste­dim Biotech, a lead­ing in­ter­na­tional sup­plier for the bio­phar­ma­ceu­ti­cal in­dus­try, and Repli­gen Cor­po­ra­tion, a global life sci­ences com­pany fo­cused on bio­pro­cess­ing tech­nolo­gies, have en­tered into a col­lab­o­ra­tion agree­ment to in­te­grate Repli­gen’s XCell ATF cell re­ten­tion con­trol tech­nol­ogy into SSB’s BIOSTAT STR large-scale sin­gle-use biore­ac­tors to cre­ate novel per­fu­sion-en­abled biore­ac­tors.

As a re­sult of this col­lab­o­ra­tion, end users will stand to ben­e­fit from a sin­gle con­trol sys­tem for 50 L to 2,000 L biore­ac­tors used in per­fu­sion cell cul­ture ap­pli­ca­tions. This sin­gle in­ter­face is de­signed to con­trol cell growth, fluid man­age­ment and cell re­ten­tion in con­tin­u­ous and in­ten­si­fied bio­pro­cess­ing and, ul­ti­mately, sim­plify the de­vel­op­ment and cGMP man­u­fac­ture of bi­o­log­i­cal drugs.

Through the part­ner­ship, Sar­to­rius Ste­dim Biotech and Repli­gen will fur­ther col­lab­o­rate to equip SSB’s re­cently launched ambr 250ht per­fu­sion sin­gle-use mini biore­ac­tor sys­tem with Repli­gen’s KrosFlo hol­low fiber fil­ter tech­nol­ogy. The biore­ac­tor sys­tem will be sold by SSB as a com­plete sin­gle-use as­sem­bly. This op­ti­mal de­sign con­serves hol­low fiber fil­ter tech­nol­ogy across scales, en­abling cus­tomers to fast track de­vel­op­ment and scale up their cell cul­ture per­fu­sion pro­cesses.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.